<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253941</url>
  </required_header>
  <id_info>
    <org_study_id>MBT-COPD2010_FORSTIII</org_study_id>
    <secondary_id>1050 FoRST</secondary_id>
    <nct_id>NCT01253941</nct_id>
  </id_info>
  <brief_title>Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Salvatore Maugeri</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rehabilitation and physical therapy strategies targeting extra pulmonary manifestations of
      Chronic Obstructive Pulmonary Disease (COPD)are far from being well defined. Studies,
      performed in healthy subjects using threshold breathing device [a simple method to increase
      inspiratory muscle load] have shown that ventilatory muscle overactivation during loaded
      breathing may prime reactive oxygen species (ROS) production, thus initiating an inflammatory
      response that results in elevation of pro-inflammatory cytokines, particularly IL_6. Increase
      of cytokine IL_6 in turn, elicits a cascade of systemic responses, involving hormone like
      glucoregulatory mechanisms, lipolysis and fat oxidation, as well as control of breathing.

      Thermal mud bath therapy has been acknowledged for its antioxidant and anti-inflammatory
      effects in several chronic diseases. However, it is not considered among treatment options of
      chronic pulmonary disease. Previous experimental studies indicate that trace elements of
      thermal treatments, particularly iodide and bromide, may positively intervene in the setup
      and maintenance of active state in skeletal muscle. These findings suggest that in COPD
      patients these elements may improve the loading and endurance of respiratory muscles and
      therefore blunt ventilatory muscle overactivation and the ensuing inflammatory cytokine
      response.

      In this study the investigators want to test two major hypotheses. First, that mud bath
      therapy reduces systemic inflammatory processes in COPD patients, increases respiratory
      muscle endurance and normalizes the ventilatory response. Second, that the increase in
      systemic inflammation after IRB exercise is blunted by mud bath therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of extra pulmonary manifestations of Chronic Obstructive Pulmonary Disease (COPD)
      on physical performance and quality of life, together with the notion that plasma cytokines
      in COPD is not due to an overflow of inflammatory mediators from the lung compartment, raise
      interest in understanding the potential link between lung and systemic inflammation.

      Recent studies, performed in normal subjects using threshold breathing device [a simple
      method to increase respiratory resistance and inspiratory muscle load] have shown that
      ventilatory muscle activation during loaded breathing may prime reactive oxygen species (ROS)
      production, thus initiating an inflammatory response within diaphragm that results in
      systemic elevation of pro-inflammatory cytokines. These findings provide a sound working
      hypothesis about the origin of systemic inflammation in COPD. Endurance and task failure of
      inspiratory muscles can be challenged during inspiratory resistive breathing (IRB) exercise
      performed with either nonlinear or threshold loading devices [4-6], thus allowing to simulate
      resistive breathing caused by airway narrowing occurring during COPD exacerbations Therapy
      with mineral water is a widely used modality of physical therapy in countries rich in mineral
      water. Up to date, however, it is not considered among treatment options of chronic pulmonary
      disease by recent guidelines. Mud bath therapy has been acknowledged for its antioxidant and
      anti-inflammatory effects in several chronic diseases. Although full mechanisms of such
      effects have not yet been fully elucidated, previous in vivo studies on the effects of
      several anions on the duration of active state in skeletal muscle indicate that trace
      elements of thermal treatments, particularly iodide and bromide, may positively intervene in
      the setup and maintenance of this active state. These findings suggest that in COPD patients
      these elements may improve the loading and endurance of respiratory muscles and therefore
      blunt ventilatory muscle overactivation and the ensuing inflammatory cytokine response.

      In this study the investigators want to test two major hypotheses. First, that mud bath
      therapy reduces systemic inflammatory processes in COPD patients, increases respiratory
      muscle endurance and normalizes the ventilatory response. Second, that the increase in
      systemic inflammation after IRB exercise is blunted by mud bath therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cytokine IL6 at 2weeks +2days (after Mud Bath Therapy)</measure>
    <time_frame>baseline test before IRB, at Day 17</time_frame>
    <description>Subjects for the study will be 42 mild-to-severe COPD outpatients. They will carry out baseline venous and arterial capillary blood sampling, ventilatory response tests and assessment of pulmonary function, before and after loaded breathing (IRB)test. Patients will then be randomized to standard mud bath therapy (12 sessions) or no-treatment. All tests and measurements will be repeated afterwards.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change before-after IRB test in cytokine IL_6, at baseline</measure>
    <time_frame>before-after IRB test, at Day 0</time_frame>
    <description>Subjects for the study will be 42 mild-to-severe COPD outpatients. They will carry out baseline venous blood sampling, before and after loaded breathing (IRB)test. Change before-after IRB test in IL_6 will be assessed at baseline(day 0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change before-after IRB test in cytokine IL_6, at 2 weeks +2 days</measure>
    <time_frame>before-after IRB test, at Day 17</time_frame>
    <description>Subjects for the study will be 42 mild-to-severe COPD outpatients. They will carry out baseline venous blood sampling, before and after loaded breathing (IRB) test. Change before-after IRB test in IL_6 will be assessed again at 2 weeks + 2days(day 17, after Mud Bath Therapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in respiratory muscle endurance time, at 2weeks +2days</measure>
    <time_frame>IRB test duration, at Day 17</time_frame>
    <description>Time duration of sustainable inspiratory pressure, set at 50% of MIP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Ventilatory Response to CO2, at 2weeks +2days</measure>
    <time_frame>Baseline test at day 17</time_frame>
    <description>Ventilatory response to CO2 (VRCO2), is conducted according to Read's technique. The subjects will be seated comfortably, attached to the mouthpiece with a noseclip in place and breathing room air until the end-tidal PCO2 (Pet,CO2) stabilized. They then will start rebreathing a mixture of approximately 7% CO2 and 93% O2. Rebreathing was continued for at least 3 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change before-after IRB test in VRCO2, at day 0</measure>
    <time_frame>before-after IRB test, at Day 0</time_frame>
    <description>Ventilatory response to CO2 (VRCO2), conducted according to Read's technique, will be obtained before and after IRB test, at day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change before-after IRB test in VRCO2, at day 17</measure>
    <time_frame>before-after IRB test, at Day 17</time_frame>
    <description>Ventilatory response to CO2 (VRCO2), conducted according to Read's technique, will be obtained before and after IRB test, at day 17</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Mud Bath therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>no Mud Bath Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mud bath Therapy</intervention_name>
    <description>patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment</description>
    <arm_group_label>Mud Bath therapy</arm_group_label>
    <other_name>Thermal treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 45 years

          -  34% &lt;/= FEV1 &lt;/= 70%

          -  stable clinical conditions

        Exclusion Criteria:

          -  idiopathic or acquired bronchiectasis

          -  cardiovascular, peripheral vascular or cerebrovascular disease

          -  systemic confounding inflammatory disease (e.g rheumatoid arthritis,Crohn's disease,
             systemic vasculitis etc.)

          -  malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simonetta Baldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Salvatore Maugeri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gian Domenico Pinna, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Salvatore Maugeri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri- Istituto Scientifico di Montescano</name>
      <address>
        <city>Montescano</city>
        <state>Pavia</state>
        <zip>27047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salvatore Maugeri Foundation - Scientific Institute of Montescano</name>
      <address>
        <city>Montescano</city>
        <state>Pavia</state>
        <zip>27047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Vassilakopoulos T, Hussain SN. Ventilatory muscle activation and inflammation: cytokines, reactive oxygen species, and nitric oxide. J Appl Physiol (1985). 2007 Apr;102(4):1687-95. Epub 2006 Dec 21. Review.</citation>
    <PMID>17185492</PMID>
  </results_reference>
  <results_reference>
    <citation>Martyn JB, Moreno RH, Par√© PD, Pardy RL. Measurement of inspiratory muscle performance with incremental threshold loading. Am Rev Respir Dis. 1987 Apr;135(4):919-23.</citation>
    <PMID>3565939</PMID>
  </results_reference>
  <results_reference>
    <citation>Nickerson BG, Keens TG. Measuring ventilatory muscle endurance in humans as sustainable inspiratory pressure. J Appl Physiol Respir Environ Exerc Physiol. 1982 Mar;52(3):768-72.</citation>
    <PMID>7068493</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <last_update_submitted>September 11, 2013</last_update_submitted>
  <last_update_submitted_qc>September 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Salvatore Maugeri</investigator_affiliation>
    <investigator_full_name>Simonetta Baldi</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>COPD, Intensive Resistive Breathing, Cytokine IL6,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

